Who Paid My Doc
Yahya Talieh
Modesto, CA Medical Doctor
NPI 1780624619 CMS profile 1311016
1401 Spanos Ct, Suite 203, Modesto, CA 95355
General payments
$11,786
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Yahya Talieh of Modesto, CA is reported in the CMS Open Payments database as having received $11,786 across 83 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $275 | 4 | |
| 2024 | General | $4,398 | 18 | |
| 2023 | General | $318 | 7 | |
| 2022 | General | $1,138 | 5 | |
| 2021 | General | $1,051 | 10 | |
| 2020 | General | $366 | 10 | |
| 2019 | General | $4,240 | 29 |
Beside peers
- Yahya Talieh
- California median
- Middle half of California
- National median
In program year 2025, general payments to Yahya Talieh were reported at $275. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Yahya Talieh | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,240 | $161 | $50–$652 | $163 |
| 2020 | $366 | $114 | $34–$392 | $114 |
| 2021 | $1,051 | $137 | $41–$509 | $132 |
| 2022 | $1,138 | $152 | $48–$573 | $149 |
| 2023 | $318 | $162 | $50–$581 | $160 |
| 2024 | $4,398 | $162 | $52–$583 | $164 |
| 2025 | $275 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
99
Drug cost
$668
Branded share of claims
75.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 53 | $415 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 22 | $175 | |
| Carvedilol | Generic | 13 | $68 | |
| Tramadol Hcl | Generic | 11 | $10 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 62 billing codesPaid by Medicare
$153,205
Medicare patients
316
Services billed
570
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 67% | |
| Diabetes | 59% | |
| Chronic kidney disease | 59% | |
| Heart failure | 51% | |
| Arthritis | 46% | |
| Atrial fibrillation | 41% | |
| COPD | 33% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
83 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.